NEW DELHI : Vaccine efficacy against severe covid-19, even for the delta variant, is so high that booster doses for the general population are not appropriate at this stage in the pandemic, a review published in The Lancet has concluded.
The review summarizes the currently available evidence from randomized controlled trials and observational studies published in peer-reviewed journals and pre-print servers.
Averaging the results reported from the observational studies, vaccination had 95% efficacy against severe disease both from the delta variant and from the alpha variant, and over 80% efficacy at protecting against any infection from these variants, noted the review.